Abstract
Germline exome sequencing (ES) commonly generated in the clinical workflow of molecular tumor boards and rare/undiagnosed disease clinics has the potential to be repurposed to support clinical pharmacogenomics (PGx). However, accurately calling PGx-relevant genotypes from exome sequencing remains challenging. In this study, we assessed the analytical validity of the computational tool, Aldy, in calling PGx-relevant genotypes from ES data for 13 major pharmacogenes.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
